Dose-intensive chemotherapy with cisplatin, vincristine, doxorubicin and etoposide against lung cancer: a pilot study.
We carried out the present study for the purpose of investigating the toxicity and efficacy of dose-intensive chemotherapy (Tokushima-CODE; T-CODE) against advanced lung cancer. Ten patients (8 with small-cell lung cancer and 2 with non-small-cell lung cancer) received chemotherapy consisting of cisplatin (27 mg/m2 on days 1-3), vincristine (0.7 mg/m2 on days 1 and 8), doxorubicin (40 mg/m2 on day 1) and etoposide (133 mg/m2 on days 1-3). Recombinant granulocyte-colony stimulating factor (75 micrograms/body on days 4-15) was injected subcutaneously. Nine patients had measurable lesions, and they all experienced partial responses. WHO grades 3 and 4 leukopenia was found in 7 out of 10 patients; thrombocytopenia (grades 3 and 4) was seen in 5 out of 10 patients during the first cycle. These results suggest that T-CODE chemotherapy is a promising induction chemotherapy.
Yanagawa
H
H
Department of Respiratory Medicine, Tokushima Prefectural Central Hospital, Japan.
Bando
H
H
Takishita
Y
Y
D000328:Adult; D000368:Aged; D000380:Agranulocytosis / Q000139:chemically induced / Q000517:prevention & control; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011994:Recombinant Proteins / Q000627:therapeutic use; D012074:Remission Induction; D013921:Thrombocytopenia / Q000139:chemically induced; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D002945:Cisplatin